

Phone: 800.511	1.5144 • Fax: 877.541.1503
Date Shipment Needed:	Ship To: ☐ Patient ☐ Prescriber
□ Nursing needed; □ Training needed ► All the supplies including syri	inges and needles will be dispensed if needed.

## RHELIMATOL OGY IV ROLLTE REFERRAL FORM

MILOMA	IOLOGI IV I	OUTE INEL ENINAL I O	I ZIVI					
PATIENT INFORMATION								
Patient Name:	DOB:	Sex: □M □F □ Other:		Weight:	□lbs. □kg.			
SSN: Phone:	Allergies:							
Address:		City:	State:	Zip:				
Emergency Contact:	Phone:		☐ Additional I	nformation Attach	ed			
PRESCRIBER INFORMATION								
Prescriber:	NPI:	DEA:	5	State Lic:				
Supervising Physician:		Practice Name:						
Address:		City:	State:	Zip:				
Phone: Fax:		Key Office Contact:		Phone:				
DIAGNOSIS INFORMATION / MEDICAL ASSESSMENT								
<b>Primary Diagnosis:</b> ☐ M06.9 Rheumatoid Arthritis ☐ L40.54; L40.59 Psoriatic Arthritis ☐ M08.00 Unspecified Juvenile Rheumatoid Arthritis ☐ M08.20 Juvenile Idiopathic Arthritis								
□ M08.3 Juvenile Rheumatoid Polyarthritis (Seronegative) □ M45.9 Ankylosing Spondylitis □ M33.20 Polymyositis □ M15.0 - M15.9 Osteoarthritis □ Other:								
■ Has patient been treated previously for this condition? □ Yes □ No Is patient currently on therapy? □ Yes □ No Please list medication(s) and treatment duration:								
<ul> <li>Will patient stop taking the above medication(s) before starting the new r</li> </ul>	nedication? ☐ Yes	☐ No If yes, how long should	patient wait before	e starting the new med	dication?			
Other medications national is a greatly taking including OTC medications with decade and direction (or fay medication profile).								
- Other medications patient is currently taking including OTO medications	Other medications patient is currently taking including OTC medications with dosage and direction (or fax medication profile):							
Has patient received a Quatiferon gold, Tspot or PPD (tuberculosis) Skin Test? ☐ Yes ☐ No Date: Results: ☐ Negative ☐ Positive								
Prior to initiating treatment and periodically during therapy, patient should								
NSURANCE INFORMATION								
☐ Please attach front and back of patient's insurance card (me	dical and prescr	iption)						
COPAY CARD ENROLLMENT	'	,						
☐ Please check if enrolling in copay card								
PRESCRIPTION INFORMATION								
STC Standard Protocol will include the following: (1) dispensing ordered m	od/doso (2) diluont	to mix and / or dilute dose (3) flus	has to flush line an	d anakit mod (oninonhr	ino 0.3 ma IM/0.15 ma IM			
(for pediatric patients) and diphenhydramine 50 mg/mL) and (4) premeds to ta								
( ) promote to ta		(a) (, that o=0g,a) . opoat x	.,	o <u>_</u> og,a, .opo.	w , .			
☐ Actemra® 20 mg/mL (Vial Sizes: 4 mL, 10 mL, 20 mL) *Maximum dose per in	nfusion is 800 mg	Starter Dose Not Needed		☐ Enroll in Access	s Solutions			
☐ Standard Dose: 4 mg/kg mg IV every 4 weeks, infus				QTY: QS	Refills:			
☐ Increased Dose: 8 mg/kg mg IV every 4 weeks, infus	ion over 60 minutes	s (infusion at MD's office or infus	ion center)	QTY: QS				
☐ Alternate Dose:				QTY:	Refills:			
- N/IO								
IVIG	om or ook vour loo	al Apprial localth rom						
☐ Home Infusion (Download IVIG referral form at www.AcariaHealth.co	orn, or ask your loca	ы Асапапеаштер)						
☐ Orencia® 250 mg IV Vial *Dosage based on patient's weight ☐ MD's o	office infusion	Infusion supplies needed		☐ Enroll in The Circle Program				
☐ Infuse mg at Weeks 0, 2 and 4, then every 4 weeks therea				QTY:   Refills:				
,								
Remicade® and Remicade® Biosimilars (Inflectra®, Renfexis®, Avsola		Avecle® 400 mm vial						
□ Remicade® 100 mg vial □ Inflectra® 100 mg vial □ Renflexis®	100 mg viai 🗀	Avsola = 100 mg vial			sOneSM Program			
☐ MD's Office Infusion ☐ Infusion Supplies Required			QTY: QS for Approp. Amt.   Refills: 0					
☐ Infuse mg IV on Weeks 0, 2, and 6				QTY: QS for Approp. Amt.   Refills: 0 QTY: QS for Approp. Amt.   Refills:				
☐ Infuse mg IV every 8 weeks			QTY: QS for Approp. Artit.   Refills:					
☐ Infuse mg IV every weeks				QTT. QS IOI Appro	p. Amt.   Reills.			
Rituxan® and Rituxan® Biosimilars ( Truxima®, Ruxience®, Riabni® )				☐ Enroll in RISE F	Program			
☐ Rituxan® 500 mg vial ☐ Truxima® 500 mg vial ☐ Ruxience® 5	•	abni® 500 mg vial			rogram			
$\square$ Infuse 1000 mg IV once every 2 weeks for 2 doses, every 16 to 24 v	veeks			QTY: 4 Vials	Refills:			
☐ Other:				QTY: QS	Refills:			
☐ Simponi® Aria 50 mg / 4 mL Single-use Vial	П	Starter Dose Not Needed						
☐ Starter Dose: 2 mg/kg mg IV on Weeks 0 and 4, ii				QTY: QS	Refills:			
☐ Maintenance Dose: 2 mg / kg mg IV every 8 weeks, infus				QTY: QS	Refills:			
☐ Alternate Dose:				QTY: QS	Refills:			
				<u> </u>				
□ Other:				QTY:	Refills:			
					· ———			
Duna anihanda Cinnatura				D-f				
Prescriber's Signature:	au the treating		spense as Written)					
rescriber certifies that this referral form contains an original signature and is signed to official state prescription blank.  In the event requested agent is not available through <i>i</i>				nere required by law, sen	u electronic prescription or on			
	, p							

IMPORTANT NOTICE: This message may contain privileged and confidential information and is intended only for the individual named. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately if you have received this document by mistake, then destroy this document. Please direct all verification or notification to AcariaHealth or any of its subsidiaries using the contact information provided on this coversheet.